456 related articles for article (PubMed ID: 27980102)
1. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
Teng KY; Han J; Zhang X; Hsu SH; He S; Wani NA; Barajas JM; Snyder LA; Frankel WL; Caligiuri MA; Jacob ST; Yu J; Ghoshal K
Mol Cancer Ther; 2017 Feb; 16(2):312-322. PubMed ID: 27980102
[TBL] [Abstract][Full Text] [Related]
2. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
3. CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway.
Zhuang H; Cao G; Kou C; Liu T
Oncol Rep; 2018 Jan; 39(1):21-30. PubMed ID: 29115520
[TBL] [Abstract][Full Text] [Related]
4. The CCR2
Bartneck M; Schrammen PL; Möckel D; Govaere O; Liepelt A; Krenkel O; Ergen C; McCain MV; Eulberg D; Luedde T; Trautwein C; Kiessling F; Reeves H; Lammers T; Tacke F
Cell Mol Gastroenterol Hepatol; 2019; 7(2):371-390. PubMed ID: 30704985
[TBL] [Abstract][Full Text] [Related]
5. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
6. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
7. PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
She S; Wu X; Zheng D; Pei X; Ma J; Sun Y; Zhou J; Nong L; Guo C; Lv P; Song Q; Zheng C; Liang W; Huang S; Li Q; Liu Z; Song Z; Li Y; Zhang Y; Kong W; You H; Xi J; Wang Y
J Hepatol; 2020 Mar; 72(3):506-518. PubMed ID: 31813573
[TBL] [Abstract][Full Text] [Related]
8. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling.
Han R; Gu S; Zhang Y; Luo A; Jing X; Zhao L; Zhao X; Zhang L
Sci Rep; 2018 Jun; 8(1):9575. PubMed ID: 29934505
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
[No Abstract] [Full Text] [Related]
10. CCL2-CCR2 signaling promotes hepatic ischemia/reperfusion injury.
Zhang J; Xu P; Song P; Wang H; Zhang Y; Hu Q; Wang G; Zhang S; Yu Q; Billiar TR; Wang C; Zhang J
J Surg Res; 2016 May; 202(2):352-62. PubMed ID: 27229110
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
[TBL] [Abstract][Full Text] [Related]
12. Antibody against granulin-epithelin precursor sensitizes hepatocellular carcinoma to chemotherapeutic agents.
Wong NC; Cheung PF; Yip CW; Chan KF; Ng IO; Fan ST; Cheung ST
Mol Cancer Ther; 2014 Dec; 13(12):3001-12. PubMed ID: 25253787
[TBL] [Abstract][Full Text] [Related]
13. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.
Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH
Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744
[TBL] [Abstract][Full Text] [Related]
14. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C
Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703
[TBL] [Abstract][Full Text] [Related]
15. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
16. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
17. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
Yao W; Ba Q; Li X; Li H; Zhang S; Yuan Y; Wang F; Duan X; Li J; Zhang W; Wang H
EBioMedicine; 2017 Aug; 22():58-67. PubMed ID: 28754304
[TBL] [Abstract][Full Text] [Related]
18. Myeloid NEMO deficiency promotes tumor immunosuppression partly via MCP1-CCR2 axis.
Yuanyuan L; Yakun L; Zhongyao L; Le Y; Weisong D; Moran G; Hui B; Chunyan L
Exp Cell Res; 2021 Feb; 399(2):112467. PubMed ID: 33428904
[TBL] [Abstract][Full Text] [Related]
19. CCL2/CCR2-dependent recruitment of Th17 cells but not Tc17 cells to the lung in a murine asthma model.
Wang A; Wang Z; Cao Y; Cheng S; Chen H; Bunjhoo H; Xie J; Wang C; Xu Y; Xiong W
Int Arch Allergy Immunol; 2015; 166(1):52-62. PubMed ID: 25765592
[TBL] [Abstract][Full Text] [Related]
20. IL-33 enhances proliferation and invasiveness of decidual stromal cells by up-regulation of CCL2/CCR2 via NF-κB and ERK1/2 signaling.
Hu WT; Li MQ; Liu W; Jin LP; Li DJ; Zhu XY
Mol Hum Reprod; 2014 Apr; 20(4):358-72. PubMed ID: 24344240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
